Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 2/20 | 0.58 |
| ▸ | ESR1 | P03372 | 4/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.58 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA3 | P07451 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | BCR | P11274 | 1/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL546705 | 0.92 | — | — | |
| SCHEMBL3149415 | 0.86 | MMP3 (0.38) | MMP3ESR1ESR2CA12CA2 | |
| SCHEMBL2322395 | 0.78 | ESR1 (0.61) | MMP3ESR1ESR2BCL2L1ABL1 | |
| SCHEMBL14400752 | 0.78 | ESR1 (0.65) | MMP3ESR1ESR2BCL2L1CA12 | |
| SCHEMBL12711690 | 0.78 | ESR1 (0.65) | MMP3ESR1ESR2BCL2L1CA12 | |
| SCHEMBL9090705 | 0.76 | ESR1 (1.00) | MMP3ESR1ESR2BCL2L1CA12 | |
| SCHEMBL30826784 | 0.76 | ESR1 (1.00) | MMP3ESR1ESR2BCL2L1CA12 | |
| SCHEMBL104811 | 0.76 | APP (0.32) | APP | |
| Hydroquinone SCHEMBL5712110 | 0.76 | ESR1 (1.00) | MMP3ESR1ESR2BCL2L1CA12 | |
| SCHEMBL15632 | 0.76 | ESR1 (1.00) | MMP3ESR1ESR2BCL2L1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265146-B2 | Integrin receptor inhibitors | GENENTECH, INC. (US) | 2007-09-04 | — | — | US | claimed |
| US-20050187284-A1 | Integrin receptor inhibitors | GENENTECH, INC. (US) | 2005-08-25 | — | — | US | claimed |
| EP-1330430-A2 | INTEGRIN RECEPTOR INHIBITORS | GENENTECH, INC. (US) | 2003-07-30 | — | — | EP | claimed |
| US-20020035104-A1 | Integrin receptor inhibitors | GENENTECH, INC. | 2002-03-21 | — | — | US | claimed |
| WO-2002016313-A2 | INTEGRIN RECEPTOR INHIBITORS | GENENTECH, INC. (US) | 2002-02-28 | — | — | WO | claimed |
| US-7265146-B2 | Integrin receptor inhibitors | GENENTECH, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20050187284-A1 | Integrin receptor inhibitors | GENENTECH, INC. (US) | 2005-08-25 | — | — | US | disclosed |
| US-6933314-B2 | Integrin receptor inhibitors | GENENTECH, INC. (US) | 2005-08-23 | — | — | US | disclosed |
| US-20040077693-A1 | Integrin receptor inhibitors | GENENTECH, INC. | 2004-04-22 | — | — | US | disclosed |
| US-6706753-B2 | 2-AMINO-FLUORENE DERIVATIVES USEFUL FOR PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH ALPHA 4 INTERGRINS OR THEIR LIGANDS | GENENTECH, INC. | 2004-03-16 | — | — | US | disclosed |
| EP-1330430-A2 | INTEGRIN RECEPTOR INHIBITORS | GENENTECH, INC. (US) | 2003-07-30 | — | — | EP | disclosed |
| US-20030100599-A1 | 2-amino-fluorene derivatives useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with alpha 4 intergrins or their ligands | GENENTECH, INC. | 2003-05-29 | — | — | US | disclosed |
| US-20020035104-A1 | Integrin receptor inhibitors | GENENTECH, INC. | 2002-03-21 | — | — | US | disclosed |
| WO-2002016313-A2 | INTEGRIN RECEPTOR INHIBITORS | GENENTECH, INC. (US) | 2002-02-28 | — | — | WO | disclosed |
| WO-1994018229-A1 | 1,2,4-TRIAZINONE DERIVATIVES AND THEIR USE IN THERAPY | FISONS CORPORATION (US) | 1994-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077693-A1 | Integrin receptor inhibitors | ITGB1, ITGA1, ITGA4 | MMP3 2407/4885ESR1 1516/4885ESR2 841/4885 |
| US-20020035104-A1 | Integrin receptor inhibitors | ITGB1, ITGA1, ITGA4 | MMP3 2407/4885ESR1 1516/4885ESR2 841/4885 |
| US-20050187284-A1 | Integrin receptor inhibitors | ITGA4, ITGB4, ITGB1 | MMP3 3363/4885ESR1 1137/4885ESR2 783/4885 |
| US-20030100599-A1 | 2-amino-fluorene derivatives useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with alpha 4 intergrins or their ligands | ITGA1, ITGA2, ITGB1 | MMP3 2638/4885ESR1 1439/4885ESR2 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.